The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable

Catheterization and Cardiovascular Interventions

Volumn 54, Issue 4, 2001, Pages 497-504

  Casterella, Peter J ^a,c   Kereiakes, Dean J ^a   Steinhubl, Steven R ^b   Raymond, Russell E ^a   Kottke Marchant, Kandice ^c   Patel, Karen ^b   Mueller, Michelle ^a   Rosenthal, Monique ^a   Moliterno, David J ^c   Teirstein, Paul S ^a  

^a SCRIPPS CLINIC   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angioplasty; Platelet aggregation inhibitors

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TICLOPIDINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLEEDING; BLOOD SAMPLING; BOLUS INJECTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; FEMALE; HEART MUSCLE REVASCULARIZATION; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; CORONARY STENOSIS; CREATINE KINASE; CREATINE KINASE, MB FORM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; FEMALE; HEMATOCRIT; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; ISOENZYMES; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; OBSERVER VARIATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035182788     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.1320     Document Type: Article

References (17)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
3. Randomized placebo-controlled trial to assess safety and efficacy of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
4. Safety and anti-platelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty: An initial experience
5. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GP IIb/IIIa receptor: Correlation with bleeding time, platelet aggregation, and blockade of GP IIb/IIIa receptors
6. Pre-clinical development of c7E fab: A mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockage of GP IIb/IIIa receptors with observations on the immunogenecity of c7E Fab in humans
7. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high risk coronary angioplasty
8. Monitoring platelet GP IIb/IIIa antagonist therapy
9. Efficacy of abciximab induced platelet blockade using a rapid point of care assay
10. Attainment and maintenance of platelet inhibition by standard dosing of abciximab in diabetic and non-diabetic patients undergoing percutaneous coronary intervention
11. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade
12. Rapid assessment of platelet function with modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy
13. Rapid-function assay: An automated and quantitative cartridge-based method
14. Sex-related differences in platelet aggregation: Influence of the hematocrit
15. The platelet membrane glycoprotein IIb/IIIa complex
16. Rapid and sustained coronary artery recanalization with combined bolus of recombinant tissue-type plasminogen activator and monoclonal antiplatelet antibody in a canine preparation
17. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (Au-Assessing Ultegra) multicenter study